Therefore, regular monitoring of CD4 cells and CD4:CD8 ratios may provide benefit if it leads to enhanced cancer screening strategies for individuals who initiate ART late and do not achieve immune restoration above 350 cells/μL and >1.0, respectively. Here, CD8A is linked to cancer.